Singapore markets open in 31 minutes

Roche Holding AG (RHO6.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
28.40-0.80 (-2.74%)
At close: 09:00PM CEST
Full screen
Previous close29.20
Open29.20
Bid28.20 x 0
Ask28.80 x 0
Day's range28.10 - 29.20
52-week range27.80 - 37.80
Volume140
Avg. volume4
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

    Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Division base business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, su

  • GlobeNewswire

    FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

    Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGF

  • Business Wire

    FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

    SOUTH SAN FRANCISCO, Calif., April 18, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and only ALK inhibitor approved for people wi